View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, July 1 (HealthDay News) -- Prescribing information for the smoking cessation drugs varenicline (Chantix) and buproprion (Zyban) must feature a boxed warning that discusses potentially serious mental health changes linked to the drugs, according to an announcement July 1 from the U.S. Food and Drug Administration.
Analysis of reports submitted to the FDA's adverse event reporting system revealed cases of unusual behavior change, new or worsening depression, and thoughts of suicide or dying among individuals taking Chantix or Zyban. In many cases, the symptoms started soon after initiating the medication and stopped when the medication was halted.
Buproprion -- marketed as Wellbutrin, an antidepressant, or available in generic form -- will contain similar warnings. The FDA recommends that clinicians prescribing Chantix or Zyban should monitor patients for unusual mood or behavior changes after they begin the medications, and patients should contact their health care provider if they notice these changes.
"The risk of serious adverse events while taking these products must be weighed against the significant health benefits of quitting smoking. Smoking is the leading cause of preventable disease, disability, and death in the United States and we know these products are effective aids in helping people quit," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research in Silver Spring, Md., in a prepared statement.
FDA News Release
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top